NCT06499896View on ClinicalTrials.gov

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2030

Conditions
Immune-mediated Colitis (IMC)Immune-related Dermatitis
Interventions
BIOLOGICAL

MTP-101-C

MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Stanley Marks Fund for Cancer Research

UNKNOWN

collaborator

Cures Within Reach

OTHER

lead

Diwakar Davar

OTHER